This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The study, called IVUS-DCB, is the first randomized controlled trial to demonstrate the clinical benefits of using IVUS in angioplasty procedures for peripheralarterydisease (PAD), a condition in which plaque builds up in arteries in the legs.
Getty Images milla1cf Mon, 02/12/2024 - 15:22 February 12, 2024 — Sensome , a company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild Smart Guidewire in peripheralarterydisease (PAD).
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheralarterydisease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with PeripheralArteryDisease (PAD).
Ruff, MD, MPH, senior investigator of TIMI Group and director General Cardiology, Cardiovascular Division, Brigham and Women's Hospital. Patient Demographics: Patients on APT had a higher rate of coronary arterydisease (70% vs. 42%), previous heart attacks (36% vs. 16%), and peripheralarterydisease (15% vs. 11%).
Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5%
Myocardial infarction (MI), stroke, peripheralarterialdisease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
New Guidelines on PeripheralArteryDisease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies 4. Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5.
In this week’s View, Dr. Eagle looks at the recently released guideline for lower extremity peripheralarterialdisease (PAD). He then examines a national community-based cohort study on contemporary decongestion strategies in patients hospitalized for heart failure.
First Procedure Performed at AHN Wexford Hospital, Demonstrating Networks Ongoing Commitment to Bringing Complex Cardiovascular Care into the Community
There are discrepancies in the literature regarding whether vorapaxar alleviates ischemic outcomes and increases bleeding in patients with peripheralarterialdisease (PAD).Purpose:The to 0.83, I2: 0%) and significantly less requirement of peripheral revascularization (RR 0.85, 95% CI 0.76 to 1.67, I2: 0%).Conclusion:In
10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb.
mtaschetta-millane Mon, 07/29/2024 - 09:16 July 29, 2024 — CorVascular , a leading producer of peripheralarterialdisease (PAD) / peripheral vascular disease (PVD) testing devices, today announced the U.S. Food and Drug Administration (FDA) has cleared its VasoGuard V-Series as Class II medical devices.
Publication date: Available online 1 May 2024 Source: The American Journal of Cardiology Author(s): Nameer Ascandar, Joseph Hadaya, Nam Yong Cho, Konmal Ali, Yas Sanaiha, Peyman Benharash
Sinai Hospital (New York, NY). We believe the tools, resources, and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues,” said SCAI President George D. PAD contributes to 400 amputations each day.
The goal of this pivotal study is to evaluate the safety and efficacy of using this device that integrates laser atherectomy and intravascular lithotripsy in a single device to treat complex, calcified lesions in a single procedure for patients with peripheralarterydisease (PAD), restoring blood flow to their legs.
a vascular surgeon and director of HonorHealth’s vascular services, said the device avoids carotid endarterectomy, a previous method for removing plaque from carotid arteries, which involves a surgical procedure requiring an incision directly into the neck. who has suffered from peripheralarterydisease for years.
10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb.
Multiple logistic regression was used to evaluate associations with major and minor amputations, major adverse cardiac events, and in‐hospital mortality. 1.04]), in‐hospital mortality (OR, 1.07 [95% CI, 1.05–1.09]), Patients were divided into 3 groups: PAD‐only, MVD‐only, or comorbid PAD/MVD. The PAD group was used as reference.
"Learn about peripheralarterydisease and its impact on 10 million Americans. The PAD Pulse Alliance launches a resource to raise awareness and provide tools f
Six multimorbidity patterns were identified, including 4 specific patterns: (1) pattern 1, cerebrovascular cluster (histories of cerebrovascular disease and hypertension); (2) pattern 2, traditional cardiovascular disease risk factors cluster (histories of hyperlipidemia, obesity, anddiabetes, and family history of cardiovascular disease and smoking); (..)
(Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheralarterialdisease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform.
Researchers analyzed more than 145 million records covering every adult patient admitted to hospital in England over a nine-year period to establish the risk of long-term health outcomes following a heart attack -- in the largest study of its kind.
Association between clusters and the composite of (i) heart failure hospitalization or all-cause death, (ii) cardiovascular (CV) hospitalization or all-cause death, and (iii) major adverse CV events was assessed. Clusters were identified using both clinical and biological variables.
Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). Elixir Medical Corporation, a privately-held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheralarterydisease.
Most have gotten used to egregiously bad coverage of current events that fills the pages of today’s New York Times, but even by their now very low standards a recent telling of a story about peripheralarterydisease was very bad. A thrombolysis is performed in the hospital via a catheter.
13, 2024Sensome hasannounced positive results from two studies of its Clotild Smart Guidewire System demonstrating its ability to successfully identify fresh clot thrombus rich in red blood cells (RBCs) in peripheralarterydisease (PAD) and differentiate it from other tissue encountered during PAD procedures. Lancet Glob.
and more likely to have coronary arterydisease, peripheralarterydisease, and chronic liver disease (p < 0.05), however they had similar CHADVASC scores (3.09 Within the cardioembolic stroke subgroup, 60.0% Patients with CVA compared to those without were younger (Age 64.9
This unique case highlights the diagnostic and therapeutic challenges of a patient with multiple vascular risk factors who suffered from strokes secondary to BHS.MethodsA 79‐year‐old man with a past medical history of peripheralarterydisease, abdominal aortic aneurysm, myocardial infarction with drug eluding stents (on dual antiplatelet therapy (DAPT)), (..)
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary arterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
years of age, P <0.001), cerebral or peripheralarterydisease (6.2% There may be no better study to symbolize the dysfunction that has invaded cardiology than the VIRGO trial, a study examining the outcomes of young patients (18-55) presenting to the hospital with a heart attack. years of age versus 59.0±8.4
Additionally, we evaluated the PAD-related hospitalizations trend stratified by age, race, sex, and geographic location.MethodsWe used the National Inpatient Sample (NIS) database from 2008 to 2020. The Cochran Armitage trend test was used to compare the trend between groups.
The multivariable logistic regression model identified female sex, chronic coronary syndrome, peripheralarterydisease and chronic kidney disease as independent factors associated with elevated BP. Conclusions These findings suggest that BP management is essential to prevent bleeding events after PCI.
Outcomes (allcause, cardiovascular, and noncardiovascular death; allcause and HF hospitalizations) were assessed by univariable and multivariable Cox regressions with EF modeled as a spline. A higher EF was characterized by more severe symptoms, hypertrophic cardiomyopathy, hypertension, female sex, and valvular disease.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content